Delivery Order SPE2DB22D1017-SPE2DB25FYRKY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,996.61 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used to treat overactive bladder. The award was competitively procured with no set-aside designation and carries a firm fixed price structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. The contract is scheduled for ultimate completion by July 15,...
- The Defense Logistics Agency awarded a delivery order valued at $4,869.59 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. The contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,257.06 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a pharmaceutical product used primarily for treating overactive bladder. The contract was competitively awarded without a set-aside designation under a firm fixed-price arrangement, with the ultimate completion date set for June 18, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania served as the place of performance. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,746.38 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication commonly used to treat overactive bladder. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025, under a firm fixed-price contract type with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $3,490.90 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. This competitively awarded, firm fixed-price contract was executed on August 29, 2025, with an ultimate completion date of September 2, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $28,170.24 by the Defense Logistics Agency (DLA) for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,109.65 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on August 11, 2025, with completion expected by August 12, 2025, this firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,013.94 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, this firm fixed-price contract utilized competitive procedures with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on September 16, 2025, with an ultimate completion date of September 17, 2025. The order, valued at $8,494.44 under a firm fixed-price contract type, covers 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,016.68 firm fixed-price delivery order is for Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract has an ultimate completion date of June 3, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYRKYDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitive delivery order from the Defense Logistics Agency (DLA) valued at $2,471.47 for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used to treat overactive bladder. The award was made under a firm fixed-price delivery order contract type with an ultimate completion date of September 22, 2025. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for pharmaceutical procurement supporting military healthcare systems worldwide. The contract carries no set-aside designation and was awarded competitively, reflecting AmerisourceBergen's established capability to meet federal medical procurement requirements. As a critical pharmaceutical distributor for the Defense Health Agency and other federal healthcare systems, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The DLA Medical Supply Chain utilizes this relationship to ensure consistent pharmaceutical availability for military personnel and veterans globally through flexible delivery order mechanisms like this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 9/19/25 |